Cambridge, MA, and Melbourne, Australia, November 24, 2014: ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Specialised Therapeutics Australia Pty Ltd (STA), today announced the marketing approval of ICLUSIG™ (ponatinib) in Australia by the Therapeutic Goods Administration (TGA). The Australian Product Information for ICLUSIG states that it is indicated for the treatment of adult patients with: Chronic
![Arctica Specialised Therapeutics](https://stabiopharma.com/wp-content/uploads/2021/03/stabio-logo.png)